NR3C2 and heart failure: Given the advancements in therapies for heart failure such as neprilysin inhibitors, sodium/glucose cotransporter 2 inhibitors, and newer generation mineralocorticoid receptor antagonists, future studies are needed to assess the efficacy of these drugs in real-world populations.